Immunotherapy in Ovarian Cancer: Thinking Beyond PD-1/PD-L1.

Front Oncol · 2021 · PMC8710491 · PMID 34966689

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

VIGIL showed a trend for an improved recurrence-free survival vs placebo (11,5 vs. 8,4 months); intriguingly, the benefit was significant among the subset with HR proficient tumors (RFS:10,6 vs 5,7mo, p=0,007)versus 55% for placebo, p=).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.